Peptide Mimetics for NMDA Receptor Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel and more specific/potent compounds that can modulate the glycine binding site of NMDA receptors with significant specificity and potency, especially for in-vivo pharmaceutical benefits, and a requirement for orally deliverable forms of such compounds to treat cognitive disorders, neuropathic pain, depression, obsessive-compulsive disorder, and schizophrenia.
Innovation Solution
Development of peptide mimetics that mimic a beta-turn structure, capable of selectively interacting with the glycine binding region of NMDA receptor NR1, including compounds with a bicyclic amide core and specific amino acid replacements, which can form hydrogen bonds with key amino acids, and methods for administering these compounds for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing partial agonists are used to modulate NMDA receptors, then some pharmacological effect is achieved, but the compounds lack sufficient specificity and potency for in-vivo pharmaceutical benefits
Solution Approach 1:
The patent modifies the chemical structure of existing partial agonists by changing molecular parameters - specifically incorporating peptide mimetics with beta-turn structures and bicyclic amide cores. These structural parameter changes enable the compounds to achieve higher specificity for the glycine binding site and greater potency in modulating NMDA receptor activity, directly resolving the contradiction between measurement precision and reliability.
Solution Approach 2:
The invention creates composite molecular structures by combining peptide mimetic elements with bicyclic amide cores and specific amino acid replacements (such as proline, glycine, and other residues at defined positions). This composite approach produces compounds that integrate multiple functional features, achieving both high specificity for NMDA receptor NR1 and enhanced pharmaceutical benefit.
2Measurement precision
If peptide mimetics with beta-turn structure are developed to increase potency, then binding affinity improves, but the complexity of compound synthesis increases
Solution Approach 1:
The patent segments the complex peptide mimetic structure into modular components - a bicyclic amide core, beta-turn structural elements, and specific amino acid side chains at defined positions. This segmentation allows for systematic variation of individual modules to optimize binding affinity while maintaining a manageable synthesis framework, reducing the overall complexity despite the sophisticated final structure.
Solution Approach 2:
The invention applies local quality by introducing specific amino acid residues at particular positions within the peptide mimetic structure (such as proline at certain positions and glycine at others) to achieve high binding affinity. These localized structural features provide the necessary beta-turn geometry and hydrogen bonding capabilities without requiring the entire molecule to be complex, thus improving binding affinity while controlling synthesis complexity.
3Ease of operation
If orally deliverable forms of compounds are developed, then therapeutic accessibility improves, but the manufacturing and formulation requirements become more stringent
Solution Approach 1:
The patent modifies the physical and chemical parameters of the peptide mimetic compounds to enhance their oral bioavailability. These parameter changes include optimizing molecular weight, lipophilicity, and metabolic stability to facilitate oral absorption and delivery. By adjusting these parameters, the compounds achieve improved therapeutic accessibility while the patent provides guidance on formulation requirements to manage manufacturing complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described compounds effectively modulate NMDA receptor activity, enhancing or reducing excitatory postsynaptic currents and long-term potentiation, and demonstrate potential in treating cognitive disorders, neuropathic pain, and psychiatric conditions by selectively interacting with the NMDA receptor NR1, offering enhanced potency compared to existing partial agonists like GLYX-13.
Implementation Method 1
capable of forming a hydrogen bond with at least one, two, three or four of the following amino acids of SEQ ID NO.1: PRO124, THR126, GLU178 and SER180
Implementation Method 2
NMDA receptor compounds may exert dual (agonist/antagonist) effect on the NMDA receptor through the allosteric sites
Data Source
Figure 1A~1B
Figure 1C~1D
Figure 2A~2B
AI summary
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain.